← All Sol-gel Technologies LTD filings

Sol-gel Technologies LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
SLGL
Sol-gel Technologies LTD
20-F: Sol-Gel Technologies Reports Increased Revenue Amidst Going Concern Doubts
Sol-Gel Technologies' 2025 revenues surged to $19.4 million from licensing deals, yet the company faces recurring losses and substantial doubt about its ability to continue as a going concern.
NASDAQ
SLGL
Sol-gel Technologies LTD
20-F: Sol-Gel Technologies Terminates Agreements with Galderma, Sells U.S. Rights to Mayne Pharma
Sol-Gel Technologies ends licensing deals with Galderma for Twyneo and Epsolay in the U.S., selling rights to Mayne Pharma and focusing on orphan drug candidates.
NASDAQ
SLGL
Sol-gel Technologies LTD
20-F: Sol-Gel Technologies Ltd. Files 20-F Annual Report, Details Financial Performance and Strategic Developments
Sol-Gel Technologies Ltd. releases its 20-F filing, outlining financial data, strategic initiatives, and key developments for the fiscal year ended December 31, 2023.